Advances in Microfluidics & Nanofluidics (AMN) 2013 is the fourth AMN conference after successful meetings previously held in Hong Kong (2009), Singapore (2011) and Dalian, China (2012). The aim of the conference is to provide a forum to promote scientific exchange and to foster closer networks and collaborative ties between leading international micro/nanofluidics researchers across various disciplines from engineering, physics, chemistry, biology, material science and biotechnology.
The scope of AMN 2013 is deliberately broad and interdisciplinary, encompassing the latest advances and the most innovative developments in micro/nanoscale science and technology. Topics range from fundamental research to its applications in chemistry, physics, biology, materials and medicine.
Abstracts for oral and poster presentations are solicited across broad themes centered around fundamentals and applications of micro/nanofluidic science and technology. These include, but are not limited to
Fundamentals in microfluidics and nanofluidics
Novel fluid and transport phenomena at microscale and nanoscale dimensions
Microscale and nanoscale fluid actuation and particle manipulation mechanisms
Chemical and biological sensing techniques
Gene, protein and cell analysis and manipulation
Chemical and biochemical synthesis
Biosensors for biochemical and pathogen detection
Drug screening and drug delivery
Biomaterials synthesis and tissue engineering
Microfuel cells and other energy/environmental applications
Micro/nanofabrication methods and chip-scale integration
The 17th International Conference on Prenatal Diagnosis and Therapy will be held in Lisbon, Portugal, 2 - 5 June 2013. Three days of podium sessions, controversies, symposia and poster sessions will follow a day of preconference courses designed for professionals around the globe engaged in prenatal diagnosis, therapy and research. We look forward to seeing you there! Please check this website for further details as they become available.
ISPD will offer preconference workshops on Sunday, 2 June 2013. ISPD 17th International Conference sessions will be held Monday – Wednesday, 3 – 5 June 2013. The three days of conference sessions will include debates on the latest controversies in the field and concurrent sessions featuring confirmed invited speakers and selected abstract presentations. Please bookmark this website and check it regularly for updates as invited speakers are confirmed.
This unique international conference will provide a platform for all pharmaceutical scientists, internists and primary care physicians to discuss and learn about important international breakthrough developments in drug discovery and on new therapeutics. The focus of the conference will be on the interdisciplinary fields of drug discovery, drug therapy and translational medicine. A similar series of conferences have been held by the organizers in the UAE over the last several years. These events have been highly successful and many top international scientists, including over 22 Nobel Laureates, have presented their work.
The 2013 IEEE/ASME International Conference on Advanced Intelligent Mechatronics will be held on July 9-12, 2013 in Wollongong. AIM 2013 conference brings together an international community of experts to discuss the state-of-the-art, new research results, perspectives of future developments, and innovative applications relevant to mechatronics, robotics, control, automation, and related areas.
The theme of the conference is “Mechatronics for Human Wellbeing”, which emphasises the significance of Mechatronics in enhancing the quality of life for society.
AIM 2013 conference invites submissions of high quality research papers describing original work on the following topics, but not limited to: Actuators, Automotive Systems, Bioengineering, Data Storage Systems, Electronic Packaging, Fault Diagnosis, Human-Machine Interfaces, Industry Applications, Information Technology, Intelligent Systems, Machine Vision, Manufacturing, Micro-Electro-Mechanical Systems, Micro/Nano Technology, Modeling and Design, Motion Vibration and Noise Control, Neural and Fuzzy Control, Opto-Electronic Systems, Prototyping, Real-Time and Hardware-in-the-Loop Simulation, Robotics, Sensors, System Integration, Transportation Systems, Smart Materials and Structures, Energy Harvesting and other frontier fields of mechatronics.
Technological advances in next generation diagnostics are driving growth and innovation in healthcare. Rapid and precise diagnosis is essential for personalized medicine and will change the way value is assessed and compensated in the healthcare system. This meeting offers a comprehensive view of the changing landscape of diagnostics and brings together the key players in the field.
The Next Generation Dx Summit (Enabling Point-of-Care Diagnostics, Cancer Molecular Markers to Guide Therapy, Molecular Diagnostics for Infectious Disease, Companion Diagnostics, Commercialization of Molecular Diagnostics, Molecular Profiling of Circulating Tumor Cells) is designed to bring together all of the major players in the evolving areas of diagnostics. This year, we have assembled an impressive faculty of speakers from industry, government, and leading academic institutions. This meeting will showcase improvements in technology research and development with an emphasis on applications in the clinic and commercialization. Plan to hear what the industry leaders are saying about future market opportunities and network with your peers this August 20-22 in Washington, DC.
We would like to invite you to join us for the 2013 EVDI Annual Scientific Meeting, jointly organized by the European College of Veterinary Diagnostic Imaging (ECVDI), the European Association of Veterinary Diagnostic Imaging (EAVDI) and the Portuguese Small Animal Veterinary Association (APMVEAC), which will take place in Cascais, Portugal from the 27th of August to the 1st of September of 2013.
The EVDI Annual Meeting brings together the latest news and advances in veterinary diagnostic imaging, with exceptional educational and scientific value.
This year we also provide an interesting selection of Continuing Professional Development Courses, specially designed for professionals who want to further develop their skills in the a wide variety of veterinary diagnostic imaging fields in small animal and equine medicine.
There is lots of excitement in this field regarding the creation and development of new tools for improving the detection, diagnosis and treatment of diseases at the molecular level. This conference will discuss the expression patterns from both the genome and proteins, and use them to differentiate between what is normal and abnormal. There will be particular focus on point-of-care diagnostics, predictive biomarkers and their discovery and detection. Additionally, the cutting-edge subjects of circulating tumour cells and diagnostic applications of exosomes will be explored, giving delegates a brilliant insight into this rapidly expanding field.
Molecular Medicine Congress will provide the latest novel applications in molecular mechanisms and therapeutic developments. It will also offer new ideas and approaches for research and offer the opportunity for scientists to collaborate with the experts in this field. Our panel of distinguished speakers will present their recent discoveries and most updated scientific information, which will make for a very exciting and rewarding conference to attend.
Our Molecular Medicine Congress 2013 is an international event being hosted in beautiful city of Frankfurt, Germany. Tracks at this event are, Diagnostic Applications of Next Gen Sequencing and Biomarkers and Applications of Exosomes. Registered delegates will have unrestricted access to both meetings ensuring a comprehensive learning and sharing experience as well as being financially beneficial for attendees.
Today, innovation is essential for the rapidly evolving diagnostics landscape. While point-of-care testing has the potential to streamline healthcare and improve clinical outcomes, regulators, and clinicians must be creative to translate this potential into a reality. Point-of-Care Diagnostics World Congress will provide an overview of the point-of-care testing landscape, from novel technologies to regulatory approval. Physicians will offer their perspective on point-of-care adoption in the clinical setting as well as in the global health environment. The aim of this meeting is to bring together life science researchers that work at the interface between biology and chemistry to discuss problems, highlight solutions and facilitating collaborations.
The conference will be co-located with Single Cell Analysis Summit, Microarray World Congress and Lab-on-a-Chip World Congress. Registered delegates will have access to all four meetings ensuring a very cost-effective trip.
The Lab-on-a-Chip World Congress will bring together leaders from both academia and industry to discuss innovative developments in this exciting field, with presentations exploring the latest advances in microfluidics and microfabrication. Attention will also be given to some of the many applications of Labs-on-Chips, from the enhancement of life science research, to taking diagnostics to the point of need.
In recent years there have been dramatic changes in the field of prenatal diagnostics, both as a result of new technical capabilities, as well as concerns over the risks and limitations associated with traditional diagnostic approaches. The transition in favor of array-based cytogenetic assays in place of traditional karyotyping is well underway. For higher risk pregnancies, the use of sequence-based testing of cell-free DNA in maternal blood is becoming more common, although evidence of genetic abnormalities must then still be confirmed with more invasive procedures. Research aimed at isolation of nucleated fetal cells from maternal blood could provide better answers with lower risk in the future. Advances in single cell sequencing are being applied to pre-implantation diagnostics and could be particularly powerful when combined with fetal cell isolation from maternal blood. Progress is also being made in the development of biomarkers to assess the risk of both pre-term labor and pre-eclampsia, which offer the potential of much earlier steps to limit these dangers. While technical developments will be important, there are also a number of other factors, including regulatory and reimbursement challenges, as well as clinical and genetic counseling perspectives, that need to be understood in order to forecast how this field is likely to develop over the next few years.